Displaying results 26 - 26 of 26
Clear search
PhoreMost Ltd and University of Cambridge collaborate to identify innovative drug targets
PhoreMost Ltd, a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. The groups will study and translate essential cellular mechanisms of neurodegenerative disorders into novel therapeutic strategies for diseases such as Parkinson’s and Alzheimer…